{"id":"W4399010918","doi":"10.1038/s41591-024-03043-1","title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Toronto; University of Alberta","funders":"National Heart, Lung, and Blood Institute; American Regent; CytoSorbents Europe; CSL Limited; LG Chem; Idorsia Pharmaceuticals; Jewish General Hospital; Novo Nordisk; Canada Excellence Research Chairs, Government of Canada; Fondation Leducq; Horizon Therapeutics; Galderma; ReCor Medical; Sanofi; Abiomed; Ionis Pharmaceuticals; Zogenix; National Institutes of Health; Regeneron Pharmaceuticals; Boston Scientific Corporation; CSL Behring; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; Amarin Corporation; AstraZeneca; AtriCure; Duke Clinical Research Institute; Astellas Pharma; Cytokinetics; University of Toronto; Alexion Pharmaceuticals; Esperion Therapeutics; Alnylam Pharmaceuticals; Daiichi Sankyo Europe; Servier; Gilead Sciences; Kowa Company; Amgen; HLS Therapeutics; LivaNova; York University; Pfizer","keywords":"Medicine; Randomized controlled trial; Dialysis; Internal medicine; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001924711,0.001253258,0.002250278,0.0003036067,0.0003998888,0.001069088,0.000629251,0.001754314,0.004189558],"category_scores_gemma":[0.001238595,0.000513846,0.001630078,0.0003081852,0.0006770106,0.0006786233,0.0003008845,0.002705544,0.0006500692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006048218,"about_ca_system_score_gemma":0.000899821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006579712,"about_ca_topic_score_gemma":0.00125207,"domain_scores_codex":[0.9995586,0.0002399079,0.00002983019,0.00006319558,0.0000468371,0.00006158371],"domain_scores_gemma":[0.9993615,0.0001654021,0.0001468361,0.00004749241,0.00006288561,0.0002158941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9570821,0.007314527,0.001020933,0.0009986341,0.001529448,0.00005402374,0.00004773975,0.000349266,0.00705279,0.00009828649,0.001534887,0.02291739],"study_design_scores_gemma":[0.959049,0.03691293,0.002064771,0.00004641019,0.0004224526,0.0000350073,0.00001199149,0.0003474785,0.0003775784,0.00006833252,0.0006536054,0.00001040624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9745519,0.01556999,0.0009597255,0.001762073,0.0006482161,0.003504464,0.001108166,0.0001445009,0.00175102],"genre_scores_gemma":[0.9806924,0.006468228,0.002006532,0.002422415,0.0005864543,0.004202136,0.001253996,0.00002609373,0.002341693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004189558,"threshold_uncertainty_score":0.01401544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006076207528880322,"score_gpt":0.2808173565854118,"score_spread":0.2747411490565315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}